CXCR4 and hepatocellular carcinoma: Moreover, co-delivery of sorafenib and mifepristone using CXCR4-targeted PLGA-PEG nanoparticles vanishs sorafenib resistance in CXCR4-expressing HCC (Zheng et al., 2019).